Sporadic<unk> S is very rare, and may have a genetic component. Clomifene citrate therapy can occasionally lead to<unk> S, but the vast majority of cases develop after use of gonadotropin therapy (with administration of FSH), such as Pergonal, and administration of hCG to induce final oocyte maturation and/or trigger oocyte release, often in conjunction with IVF. The frequency varies and depends on a woman's risk factors, management, and methods of surveillance. About 5% of treated women may encounter moderate to severe<unk> S. Risk factors include polycystic ovary syndrome, young age, low BMI, high antral follicle count, the development of many<unk>  follicles under stimulation, extreme elevated serum estradiol concentrations, the use of hCG for final oocyte maturation and/or release, the continued use of hCG for luteal support, and the occurrence of a pregnancy (resulting in hCG production). Mortality is low, but several fatal cases have been reported. Medications<unk>  is particularly associated with injection of a hormone called human chorionic gonadotropin (hCG) which is used for inducing final oocyte maturation and/or triggering oocyte release. The risk is further increased by multiple doses of hCG after ovulation and if the procedure results in pregnancy. Using a GnRH agonist instead of hCG for inducing final oocyte maturation and/or release results in an elimination of the risk of<unk> , but a slight decrease of the delivery rate of approximately 6%.
Ovarian hyperstimulation syndrome
Gonadotropin-resistant ovary syndrome
Postpartum physiological changes
Obstetric transition
Anovulation
Puppy pregnancy syndrome
Cryptic pregnancy
Lactational amenorrhea